Repro Med Systems, Inc. (KRMD)
| Previous close | 2.1000 |
| Open | 2.0500 |
| Bid | 1.0000 x 1000 |
| Ask | 3.0000 x 800 |
| Day's range | 2.0000 - 2.1900 |
| 52-week range | 1.9000 - 4.8300 |
| Volume | |
| Avg. volume | 40,785 |
| Market cap | 96.916M |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1310 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.33 |
- Simply Wall St.
What You Need To Know About Repro Med Systems, Inc.'s (NASDAQ:KRMD) Investor Composition
Every investor in Repro Med Systems, Inc. ( NASDAQ:KRMD ) should be aware of the most powerful shareholder groups...
- Business Wire
KORU Medical Systems Announces 2022 First Quarter Financial Results
CHESTER, N.Y., May 04, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022.
- Business Wire
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of EMPAVELI® (pegcetacoplan), Expands European Label for FreedomEdge®
CHESTER, N.Y., May 02, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® and c
